Key Takeaway: Cencora has launched a new service through Accelerate Pharmacy Solutions to assist health systems in evaluating, building, and scaling cell and gene therapy programs. This initiative aims to enhance operational readiness and execution, ultimately reducing barriers to care and improving patient access to advanced therapies. The service reflects a commitment to advancing healthcare solutions.
Price reaction · baseline $330.97 (2026-09-01 close) · hit pre-market · clean, no other COR news in the window
day 0 close · peak
+1.6%
Market Sentiment Analysis
POSITIVE FACTORS
Launch of a new service to support health systems
Focus on expanding patient access to advanced therapies
Aims to strengthen operational readiness for CGT programs
Full Press Release Details
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies. “Cell and gene therapies have the potential to transform care for patients with serious and compl
Frequently Asked Questions
What is Cencora's new service about?
Cencora's new service helps health systems evaluate, build, and scale cell and gene therapy programs.
How does the service benefit health systems?
The service enhances operational readiness and reduces barriers to care for advanced therapies.
What is the goal of the Cell and Gene Therapy Enablement?
The goal is to expand patient access to advanced therapies through improved program execution.